DOCSLIB.ORG

CDM WEB-Aug-W

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Charge# Description Price 0013144 ROOM CARE SEMI PRIVATE-2T 2T 5,181.00 0013169 ROOM CARE SEMI PRIVATE -P4 P4 5,544.00 0013177 ROOM CARE SEMI PRIV-OVERFLOW 72400 5,544.00 0013185 ROOM CARE SEMI PRIV-2S 2S 5,544.00 0013193 ROOM CARE SEMI PRIV - 76410 5,544.00 0013201 ROOM CARE SEMI PRIV-61703 5,544.00 0014001 ROOM CARE MED-SURG SEMI PRIV-1N 5,544.00 0014050 ROOM CARE SEMI PRIVATE-SUR SUR 5,544.00 0014134 ROOM CARE SEMI PRIV-EHD EHD 5,181.00 0015008 ROOM CARE SEMI PRIVATE -P2S P2 5,544.00 0015081 ROOM CARE SEMI PRIV-P4 P4 5,544.00 0015206 ROOM CARE SEMI PRIVATE-1T 1T 5,544.00 0015222 ROOM CARE SEMI PRIVATE-3T 3T 5,544.00 0015255 ROOM CARE SEMI-PRIV-4T 4T 5,544.00 0016303 ROOM CARE SEMI PRIV-OVERFLOW 60300 5,544.00 0016402 ROOM CARE SEMI PRIV-2W 2W 5,544.00 0017004 ROOM CARE SEMI PRIV-SAU SAU 5,544.00 0017053 ROOM CARE SEMI-PRIV-PACU PACU 5,544.00 0017103 ROOM CARE SEMI PRIVATE-CC1 CC1 5,544.00 0017202 ROOM CARE SEMI-PRIVATE-CC2 CC2 5,544.00 0017301 ROOM CARE SEMI-PRIVATE-3PZ 3PZ 5,544.00 0017319 ROOM CARE SEMI-PRIVATE-4PZ 4PZ 5,544.00 0017335 ROOM CARE SEMI-PRIV OVRFLOW 61705 5,544.00 0017343 ROOM CARE SEMI PRIV-77401 5,544.00 0017350 ROOM CARE SEMI PRIV-P4 P4 5,544.00 0017400 ROOM CARE SEMI-PRIV-4PZ 4PZ 5,544.00 0023143 ROOM CARE TELEMETRY-2T 2T 6,470.00 0023168 ROOM CARE NURSERY-P4 2,237.00 0023176 ROOM CARE TELEMETRY-OVERFLOW 72400 6,923.00 0023184 ROOM CARE TELEMETRY-2S 2S 6,923.00 0023200 ROOM CARE TELEMETRY-61703 6,923.00 0024059 ROOM CARE PRIVATE-SUR SUR 5,544.00 0024133 ROOM CARE TELEMETRY EHD EHD 6,470.00 0024141 ROOM CARE TELEMETRY-CATH LAB CLB 6,923.00 0025007 ROOM CARE NURSERY-P2 P2 2,237.00 0025031 ROOM CARE NURSERY-NSY NSY 2,237.00 0025049 ROOM CARE NURSERY-NICU NIN 2,237.00 0025072 ROOM CARE NURSERY-P3 P3 2,237.00 0025080 ROOM CARE TELEMETRY-P4 P4 6,923.00 0025205 ROOM CARE TELEMETRY-1T 1T 6,923.00 0025221 ROOM CARE TELEMETRY-3T 3T 6,923.00 0025254 ROOM CARE TELEMETRY-4T 4T 6,923.00 0026302 ROOM CARE TELEMETY-OVERFLOW 60300 6,923.00 0027003 ROOM CARE TELEMETRY-SAU SAU 6,923.00 0027052 ROOM CARE TELEMETRY-PACU PACU 6,923.00 0027102 ROOM CARE TELEMETRY-CC1 CC1 6,923.00 0027201 ROOM CARE TELEMETRY-CC2 CC2 6,923.00 0027300 ROOM CARE TELEMETRY-3PZ 3PZ 6,923.00 0027318 ROOM CARE TELEMETRY-4PZ 4PZ 6,923.00 0027334 ROOM CARE TELEMETRY-OVERFLOW 61705 6,923.00 0027342 ROOM CARE TELEMETRY-77401 6,923.00 0027359 ROOM CARE TELEMETRY-P4 P4 6,923.00 0027409 ROOM CARE TELEMETRY-4PZ 4PZ 6,923.00 0033167 ROOM CARE PERINATOLOGY-P4 P4 6,208.00 0034058 ROOM CARE ICU INTENSIVE-SUR SUR 13,336.00 0034082 ROOM CARE TCU-1S LEVEL III 1S 2,475.00 0034140 ROOM CARE INTERMEDT-CATH LAB CLB 10,124.00 0035006 ROOM CARE PERINATOLOGY-P2 P2 6,208.00 0035048 ROOM CARE NICU SURVEILLANCE NIN 8,903.00 0035071 ROOM CARE PERINATOLOGY-P3 P3 6,208.00 0037002 ROOM CARE ICU INTENSIVE-SAU SAU 11,541.00 0037051 ROOM CARE ICU INTENSIVE-PACU PACU 11,541.00 0037101 ROOM CARE ICU INTENSIVE-CC1 CC1 13,336.00 0037200 ROOM CARE ICU INTENSIVE-CC2 CC2 13,336.00 0037309 ROOM CARE ICU INTENSIVE-3PZ 3PZ 13,336.00 0043141 ROOM CARE ADMIN DAY-2T LOW SNF 2T 1,858.00 0043166 ROOM CARE SEMI PRIV LDRP-P4 P4 5,792.00 0043174 ROOM CARE ADMIN DAY-LOW SNF 72400 1,858.00 0043182 ROOM CARE ADMIN DAY-2S LOW SNF 2S 1,858.00 0043208 ROOM CARE ADMIN DAY-LOW SNF 61703 1,858.00 0044008 ROOM CARE ADMIN DAY-1N LOW SNF 1N 1,858.00 0044081 ROOM CARE ADMIN DAY-1N LOW SNF 1S 1,858.00 0045005 ROOM CARE SEMI PRIV LDRP-P2 P2 5,792.00 0045039 ROOM CARE NURSERY-INTERMED NSY 8,903.00 0045047 ROOM CARE NICU INTERMED NIN 8,903.00 0045070 ROOM CARE SEMI PRIV LDRP-P3 P3 5,792.00 0045088 ROOM CARE ADMIN DAY P4 LOW SNF P4 1,858.00 0045203 ROOM CARE ADMIN DAY-1T LOW SNF 1T 1,858.00 0045229 ROOM CARE ADMIN DAY-3T LOW SNF 3T 1,858.00 0045252 ROOM CARE ADMIN DAY-4T LOW SNF 4T 1,858.00 0046300 ROOM CARE ADMIN DAY-LOW SNF 60300 1,858.00 0047100 ROOM CARE ADMIN DAY-CC1 LOW SNF CC1 1,858.00 0047209 ROOM CARE ADMIN DAY-CC2 LOW SNF CC2 1,858.00 0047308 ROOM CARE ADMIN DAY-3PZ LOW SNF 3PZ 1,858.00 0047316 ROOM CARE ADMIN DAY-4PZ LOW SNF 4PZ 1,858.00 0047340 ROOM CARE ADMIN DAY LOW SNF-77401 1,858.00 0047357 ROOM CARE ADMIN DAY P4 LOW SNF P4 1,858.00 0047407 ROOM CARE ADMIN DAY-4PZ LOW SNF 4PZ 1,858.00 0053140 ROOM CARE ADMIN HIGH SUB ACUTE-2T 2,000.00 0053173 ROOM CARE ADMIN HI SUB ACUTE-72400 2,000.00 0053181 ROOM CARE ADMIN HIGH SUB ACUTE-2S 2,000.00 0053207 ROOM CARE ADMIN HI SUB ACUTE-61703 2,000.00 0054007 ROOM CARE ADMIN HIGH SUB ACUTE-1N 2,000.00 0054080 ROOM CARE ADMIN HIGH SUB ACUTE-1S 2,000.00 0055038 ROOM CARE NURSERY-NICU INTENSV NSY 22,521.00 0055046 ROOM CARE NICU INTENSIVE NIN 22,521.00 0055079 ROOM CARE SEMI PRIV P3 5,544.00 0055087 ROOM CARE ADMIN HIGH SUB ACUTE-P4 2,000.00 0055202 ROOM CARE ADMIN HIGH SUB ACUTE-1T 2,000.00 0055228 ROOM CARE ADMIN HIGH SUB ACUTE-3T 2,000.00 0055251 ROOM CARE ADMIN HIGH SUB ACUTE-4T 2,000.00 0056309 ROOM CARE ADMIN HIGH SUB ACUTE60300 2,000.00 0057109 ROOM CARE ADMIN HIGH SUB ACUTE-CC1 2,000.00 0057208 ROOM CARE ADMIN HIGH SUB ACUTE-CC2 2,000.00 0057307 ROOM CARE ADMIN HIGH SUB ACUTE-3PZ 2,000.00 0057315 ROOM CARE ADMIN HIGH SUB ACUTE-4PZ 2,000.00 0057349 ROOM CARE ADMIN HI SUB ACUTE-77401 2,000.00 0057356 ROOM CARE ADMIN HIGH SUB ACUTE-P4 2,000.00 0057406 ROOM CARE ADMIN HIGH SUB ACUTE-4PZ 2,000.00 0063198 ROOM CARE DOU/ONCOLOGY - 76410 5,544.00 0063206 ROOM CARE DOU/ONCOLOGY-61703 1,055.00 0064055 ROOM CARE INTERMEDIATE SUR SUR 10,124.00 0064147 ROOM CARE INTENS CARE-CLB CLB 13,336.00 0065078 ROOM CARE DOU/ONCOLOGY-P3 P3 1,055.00 0065086 ROOM CARE DOU/ONCOLOGY-P4 P4 5,544.00 0065250 ROOM CARE DOU/ONCOLOGY-4T 4T 5,544.00 0073163 ROOM CARE TELEMETRY-OBS-IPT-P4 P4 6,923.00 0074005 ROOM CARE ARC SEMI PRIVATE - 1N 3,419.00 0074088 ROOM CARE ARC SEMI PRIVATE - 1S 3,419.00 0075077 ROOM CARE ADMIN DAY P3 LOW SNF P4 1,858.00 0083162 ROOM CARE SEMI PRIV-OBS/IPT-P4 P4 5,544.00 0083188 ROOM CARE SEMI PRIVATE-2N 2N 3,195.00 0084087 ROOM CARE TCU-1S HOSPICE 1S 2,475.00 0085076 ROOM CARE ADMIN HIGH SUB ACUTE-P4 2,000.00 0094003 ROOM CARE SEMI PRIVATE-1N 1N 3,419.00 0094086 ROOM CARE TCU-1S LEVEL 3 1S 2,475.00 0100016 SUTURE VALVE 3,175.00 0100024 SUTURE CABG W/AV/MV 3,614.00 0100032 SUTURE CABG 1,591.00 0100446 ORSDS MAJOR B 1/4 HR 1,126.00 0100453 ORSDS MAJOR B 4,655.00 0100461 ORSDS MAJOR A 1/4 HR 1,298.00 0100487 ORSDS MAJOR A 5,273.00 0100503 ORSDS RECOVERY RM B 564.00 0100552 URETERAL GUIDE WIRE 129.00 0100602 CORNEAL PROCESSING-TISSUE ANGIOGDYE 8,067.00 0100610 CRYO PROBES 6,050.00 0100628 MINOR SURG-D 1/2 HR 5,516.00 0100636 MINOR SURG-D 1/4 HR 467.00 0100651 MINOR SURG-C 1/4 HR 659.00 0100982 UTERINE MANIPULATOR 148.00 0101097 TOURNIQUET 204.00 0101557 melatonin 3 mg tablet 2.25 0102962 MAJOR SURG-A 1 HR 14,816.00 0102970 MAJOR SURG-A 1/4 HR 1,844.00 0103721 MAJOR SUTURE SET 605.00 0103739 MINOR SUTURE SET 328.00 0103812 CENTRIMED PUMP-OR 3,259.00 0104059 MAJOR SUTURE A SET 1,241.00 0104406 CUSA STRAIGHT/CURVED 1,435.00 0104505 ONCOTECH ASSAY KIT 6,281.00 0104547 KIT ICU VENTRICULOSTOMY 532.00 0104646 ORSDS GENERAL SUTURE MINOR 565.00 0104653 ORSDS GENERAL SUTURE MAJOR 850.00 0104661 ORSDS EYE SUTURE 1,126.00 0104729 CABG OR SERVICES 36,828.00 0104752 MINOR C WITH LASER 15,946.00 0104760 MAJOR B WITH HIGH TECH 23,023.00 0104778 MAJOR A WITH HIGH TECH 30,955.00 0104786 COSMETIC 1/4 HR SSS 110.00 0104794 COSMETIC A 1 HR SSS 990.00 0104836 MINOR SURG-C 1 HR 9,618.00 0109165 BARD UROLOGIST TRAY 840.00 0109173 KII BALLOON BLUNT TIP SYSTEM 84.00 0109199 SEPRAFILM 1,020.00 0109207 MINICAP EXTENDED LIFE PD 230.00 0109215 MINICAP W/POVIDONE IODINE 21.00 0201079 RECOVERY ROOM A 1 HR 4,302.00 0201103 RECOVERY ROOM A 1/4 HR 613.00 0300244 ANES LOCAL/MAC ANESTH 798.00 0300426 ACTIVATED CLOTTING TIME (ACT) 678.00 0300590 ANES SDS GENERAL ANESTHESIA 1,862.00 0300608 ANES SDS MAC ANESTHESIA 745.00 0300780 IABP BALLOON CATHETER 4,692.00 0300798 IABP FO BALLOON CATHETER 5,414.00 0300806 GEN ANES 3HRS OR LESS 4,577.00 0300814 GEN ANES OVER 3 HOURS 14,916.00 0400218 DIABETES OP TRG-INDIVIDUAL 60 MIN 492.00 0400226 DIABETES OP TRG-GROUP 60MIN 285.00 0401448 DIABETES EDUCATION CLASS SERIES 75.00 0401455 DIABETES EDUCATION GESTATIONAL 17.00 0401505 DIABETES EDUCATION INDIVIDUAL 17.00 0401604 SSS SPINAL TAP 2,648.00 0608091 SDS MINOR C 1/4 HR 924.00 0608109 SDS RECOVERY RM A 1/4 HR 299.00 0608133 SDS MAJOR A 1/4 HR 1,555.00 0608141 SDS MINOR C 1/2 HR 5,516.00 0608158 SDS MAJOR A 1 HR 8,301.00 0608166 SDS RECOVERY RM A 1 HR 1,763.00 0608174 SDS RECOVERY RM B 559.00 0608398 SDS EYE SUTURE 1,126.00 0608406 SDS GENERAL SUTURE 3> PKG 850.00 0608414 SDS GENERAL SUTURE 1-3 PKG 565.00 0608463 SDS SCLERAL TISSUE 1,343.00 0608547 SDS MINOR HIGH TECH 15,946.00 0608554 SDS MAJOR HIGH TECH 17,771.00 0608562 COSMETIC A 1 HR 990.00 0608570 COSMETIC B 1/2 HR 605.00 0608588 COSMETIC 1/4 HR 110.00 0608638 SDS CONNECTIVE TISSUE,HUMAN 1,343.00 0615088 BREAST IMPLANT 4,232.00 0700039 AMNIOCENTESIS 974.00 0700047 LD CERCLAGE 12,453.00 0700062 LD FETAL MONITORING 343.00 0700096 LD MINOR SURG 1 HR 5,516.00 0700120 LD OR MAJOR SURG 3,593.00 0700161 NON-STRESS TEST 1,220.00 0705004 LD VAGINAL DELIVERY 8,603.00 0705020 L&D C-SECTION SURGERY 9,209.00 0705038 LD OB RECOVERY ROOM 2,108.00 0705046 OB OBS IV PUSH INITIAL 980.00 0705053 OB OBS INFUSION HYDR ADDL HR (>31M) 200.00 0705061 OB OBS SUBQ/1M INJECTION 531.00 0705079 OB OBS CATH INSERTION 357.00 0705087 OB OBS IV INFUSION HYDR 31-60M INTL 1,167.00 0705095 OB OBS IV PUSH ADDL NEW DRUG 735.00 0705103 BLOOD PATCH OB 1,457.00 0705129 I&D OF VULVA/PERINEUM 670.00 0705137 OUTPATIENT OBS HR ONE P2 MOD 25 300.00 0705145 OUTPATIENT OBS EA ADDL HR P2 MOD25 300.00 0705152 OB
Recommended publications
  • Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23rd - Rooms 1,2 and 3 Presentation Date Abstract Authors Presenter´s name - Theme Title Code indicated by the author 18498 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of PERFORMANCE OF AN IMMUNOASSAY Eric Franssen; Milly Attema-de abuse METHOD FOR GAMMA-HYDROXYBUTYRIC Jonge ACID (GHB) IN PATIENTS PRESENTED AT THE EMERGENCY DEPARTMENT, A PROSPECTIVE STUDY 18499 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of DO WE NEED POINT-OF-CARE TESTING OF Milly Attema-de Jonge; Eric abuse GAMMA-HYDROXYBUTYRIC ACID (GHB) AT Fransse THE EMERGENCY DEPARTMENT? September 23 18730 Lilian H.J. Richter; Julia Menges; Lea Wagmann Clinical Toxicology/drugs of NEW PSYCHOACTIVE SUBSTANCES: Lea Wagmann; Simon D. Brandt; abuse METABOLIC FATE, ISOZYME-MAPPING, 13:30 - 14:45 Folker Westphal; Veit Flockerzi; AND PLASMA PROTEIN BINDING OF 5-APB- ROOM 1 Markus R. Meyer NBOME, 2C-B-FLY-NB2ETO5CL, AND 2C-B- FLY-NBOME 18985 Annelies Cannaert; Marie Annelies Cannaert Clinical Toxicology/drugs of HIDE AND SEEK: OVERCOMING THE Deventer; Melissa Fogarty; abuse MASKING EFFECT OF OPIOID Amanda L.A. Mohr; Christophe P. ANTAGONISTS IN ACTIVITY-BASED Stove SCREENING TESTS 18740 Souleiman El Balkhi ; Roland Souleiman El Balkhi Clinical Toxicology/drugs of METABOLIC INTERACTIONS BETWEEN Lawson; Franck Saint-Marcoux abuse OXYCODONE, BENZODIAZEPINES OR DESIGNER BENZODIAZEPINES PLAY AN IMPORTANT ROLE IN OXYCODONE INTOXICATIONS 19050 Brenda de Winter F de Velde; MN Brenda de Winter Anti-infective drugs POPULATION
  • Learner Notification International Society for Heart & Lung

    Learner Notification International Society for Heart & Lung

    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
  • PPE Requirements Hazardous Drug Handling

    PPE Requirements Hazardous Drug Handling

    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
  • Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin)

    Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin)

    Luckenbach et al.: Isoelectric focussing of thyropexin and transthyretin 387 Eur. J. Clin. Chem. Clin. Biochem. Vol. 30, 1992, pp. 387-390 © 1992 Walter de Gruyter & Co. Berlin · New York Isoelectric Focussing of Human Thyroxine Binding Globulin (Thyropexin) and Human Prealbumin (Transthyretin) By Christine Luckenbach^ R. Wahl2 and E. Kailee2 1 Institut fur Anthropologie und Humangenetik 2 Medizinische Klinik und Poliklinik, Abteilung IV Eberhard-Karls- Universität Tübingen (Received November 7, 1991/Aprü 22, 1992) Summary: Two batches of the highly purified thyroid hormone-binding plasma proteins, human thyropexin and transthyretin, which were prepared in gram quantities for use in animal experiments, were subjected to analysis by isoelectric focussing. Under these conditions, it was observed that human transthyretin was composed of two components. This was presumably due to the use of 8 mol/1 urea. The preparations of both human transthyretin and human thyropexin contained some products of decomposition which probably arose in the course of the purification processes and, in addition, possibly also contained some normal genetic variants of human thyropexin. In spite of the alterations, both protein preparations largely retained their thyroid hormone-binding capacity, which is essential for in vivo studies on the re-entry of thyroid hormones from the extravascular space into the circulation. For therapeutic use in thyrotoxicosis, human transthyretin seems to be preferable to human thyropexin. Introduction The main thyroid hormone-binding plasma proteins severe thyrotoxicosis in emergencies: The concentra- in humans are thyropexin (1) ("TGB", human thy- tion of both T4 and T3 in the plasma can be signifi- roxine binding inter-alpha globulin (2))1) and trans- cantly enhanced by i.v.
  • Management of Status Epilepticus

    Management of Status Epilepticus

    Published online: 2019-11-21 THIEME Review Article 267 Management of Status Epilepticus Ritesh Lamsal1 Navindra R. Bista1 1Department of Anaesthesiology, Tribhuvan University Teaching Address for correspondence Ritesh Lamsal, MD, DM, Department Hospital, Institute of Medicine, Tribhuvan University, Nepal of Anaesthesiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Tribhuvan University,Kathmandu, Nepal (e-mail: [email protected]). J Neuroanaesthesiol Crit Care 2019;6:267–274 Abstract Status epilepticus (SE) is a life-threatening neurologic condition that requires imme- diate assessment and intervention. Over the past few decades, the duration of seizure Keywords required to define status epilepticus has shortened, reflecting the need to start thera- ► convulsive status py without the slightest delay. The focus of this review is on the management of con- epilepticus vulsive and nonconvulsive status epilepticus in critically ill patients. Initial treatment ► neurocritical care of both forms of status epilepticus includes immediate assessment and stabilization, ► nonconvulsive status and administration of rapidly acting benzodiazepine therapy followed by nonbenzodi- epilepticus azepine antiepileptic drug. Refractory and super-refractory status epilepticus (RSE and ► refractory status SRSE) pose a lot of therapeutic problems, necessitating the administration of contin- epilepticus uous infusion of high doses of anesthetic agents, and carry a high risk of debilitating ► status epilepticus morbidity as well as mortality. ► super-refractory sta- tus epilepticus Introduction occur after 30 minutes of seizure activity. However, this working definition did not indicate the need to immediately Status epilepticus (SE) is a medical and neurologic emergency commence treatment and that permanent neuronal injury that requires immediate evaluation and treatment. It is associat- could occur by the time a clinical diagnosis of SE was made.
  • North Fork of the St. Lucie River Floodplain Vegetation Technical Report

    North Fork of the St. Lucie River Floodplain Vegetation Technical Report

    NORTH FORK ST. LUCIE RIVER FLOODPLAIN VEGETATION TECHNICAL REPORT WR-2015-005 Coastal Ecosystem Section Applied Sciences Bureau Water Resources Division South Florida Water Management District Final Report July 2015 i Resources Division North Fork of the St. Lucie River Floodplain Vegetation Technical Report ACKNOWLEDGEMENTS This document is the result of a cooperative effort between the Coastal Ecosystems Section of South Florida Water Management District (SFWMD) and the Florida Department of Environmental Protection (FDEP), Florida Park Service (FPS) at the Savannas Preserve State Park in Jensen Beach, Florida and the Indian River Lagoon Aquatic Preserve Office in Fort Pierce, Florida. The principle author of this document was as follows: Marion Hedgepeth SFWMD The following staff contributed to the completion of this report: Cecilia Conrad SFWMD (retired) Jason Godin SFWMD Detong Sun SFWMD Yongshan Wan SFWMD We would like to acknowledge the contributions of Christine Lockhart of Habitat Specialist Inc. with regards to the pre-vegetation plant survey, reference collection established for this project, and for her assistance with plant identifications. We are especially grateful to Christopher Vandello of the Savannas Preserve State Park and Laura Herren and Brian Sharpe of the FDEP Indian River Lagoon Aquatic Preserves Office for their assistance in establishing the vegetation transects and conducting the field studies. And, we would like to recognize other field assistance from Mayra Ashton, Barbara Welch, and Caroline Hanes of SFWMD. Also, we would like to thank Kin Chuirazzi for performing a technical review of the document. ii North Fork of the St. Lucie River Floodplain Vegetation Technical Report TABLE OF CONTENTS Acknowledgements ..........................................................................................................................ii List of Tables ...............................................................................................................................
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
  • Critical Access COVID-19 Drugs Shortages (156-40)

    Critical Access COVID-19 Drugs Shortages (156-40)

    Resilient Drug Supply Project: Critical Acute Drug List & Critical COVID-19 Drug List Drug Shortages Reported by ASHP & FDA Shortages as of 8/22/2021 UMN RDSP UMN RDSP ASHP FDA Drug Critical Acute Drugs Drug Category List of 156 List of 40 Drug Drug # Generic Name Critical Acute Critical Shortage Shortage Drugs COVID-19 List List Drugs 1 Cisatracurium Paralytic X X Yes 2 Rocuronium Paralytic X X Yes 3 Vecuronium Paralytic X X Yes Yes 4 Succinylcholine Paralytic X X 5 Atracurium Paralytic X 6 Propofol Sedation X X Yes Yes 7 Midazolam Sedation X X Yes Yes 8 Lorazepam Sedation X X Yes Yes 9 Dexmedetomidine Sedation/Anesthesia X X Yes Yes 10 Phenobarbital Sedation X 11 Ketamine Sedation/Anesthesia X X Yes Yes 12 Diazepam Sedation X 13 Lidocaine Local Anesthetic X Yes Yes 14 Bupivacaine Local Anesthetic X Yes Yes 15 Fentanyl Pain X X Yes Yes 16 Hydromorphone Pain X X Yes Yes 17 Morphine Pain X X Yes Yes 18 Oxycodone Pain X X 19 Acetaminophen Pain & Fever X 20 Ketorolac Pain X Yes Yes 21 Anakinra Pain X 22 Oxygen Medical Gas X X 23 Nitric Oxide Medical Gas X 24 Sevoflurane Medical Gas X 25 Albuterol Bronchodilator X X Yes 26 Ipratropium (Inhaler) Bronchodilator X 27 Azithromycin Anti-infective X X 28 Piperacillin-Tazobactam Anti-infective X X 29 Cefepime Anti-infective X X Yes 30 Ceftriaxone Anti-infective X 31 Vancomycin Anti-infective X X Yes 32 Doxycycline Anti-infective X 33 Meropenem Anti-infective X X 34 Cefazolin Anti-infective X X Yes Yes 35 Levofloxacin Anti-infective X 36 Linezolid Anti-infective X 37 Ampicillin-Sulbactam Anti-infective
  • 2015 Annual Report

    2015 Annual Report

    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
  • Monoclonal Antibodies Against Cd30 Lacking In

    Monoclonal Antibodies Against Cd30 Lacking In

    (19) TZZ_97688¥_T (11) EP 1 976 883 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) A61P 35/00 (2006.01) 03.10.2012 Bulletin 2012/40 A61P 37/00 (2006.01) (21) Application number: 07718000.8 (86) International application number: PCT/US2007/001451 (22) Date of filing: 17.01.2007 (87) International publication number: WO 2007/084672 (26.07.2007 Gazette 2007/30) (54) MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES MONOKLONALE ANTIKÖRPER GEGEN CD30 OHNE FUCOSYL- UND XYLOSYLRESTE ANTICORPS MONOCLONAUX ANTI-CD30 DEPOURVUS DE RESIDUS FUCOSYL ET XYLOSYL (84) Designated Contracting States: • WANG, Ming-Bo AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Canberra Australian Capital Territory 2617 (AU) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Tuxworth, Pamela M. Designated Extension States: J A Kemp RS 14 South Square Gray’s Inn (30) Priority: 17.01.2006 US 759298 P London WC1R 5JJ (GB) 07.04.2006 US 790373 P 11.04.2006 US 791178 P (56) References cited: 09.06.2006 US 812702 P WO-A-03/059282 US-A1- 2004 261 148 11.08.2006 US 837202 P 11.08.2006 US 836998 P • P. BORCHMANN ET AL.: "The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity (43) Date of publication of application: against malignant lymphoma." BLOOD, vol. 102, 08.10.2008 Bulletin 2008/41 no.
  • Personalized Medicine for Reconstruction of Critical-Size Bone

    Personalized Medicine for Reconstruction of Critical-Size Bone

    www.nature.com/npjregenmed ARTICLE OPEN Personalized medicine for reconstruction of critical-size bone defects – a translational approach with customizable vascularized bone tissue ✉ Annika Kengelbach-Weigand 1 , Carolina Thielen 1, Tobias Bäuerle2, Rebekka Götzl 1,5, Thomas Gerber3, Carolin Körner4, Justus P. Beier1,5, Raymund E. Horch 1 and Anja M. Boos1,5 Tissue engineering principles allow the generation of functional tissues for biomedical applications. Reconstruction of large-scale bone defects with tissue-engineered bone has still not entered the clinical routine. In the present study, a bone substitute in combination with mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC) with or without growth factors BMP-2 and VEGF-A was prevascularized by an arteriovenous (AV) loop and transplanted into a critical-size tibia defect in the sheep model. With 3D imaging and immunohistochemistry, we could show that this approach is a feasible and simple alternative to the current clinical therapeutic option. This study serves as proof of concept for using large-scale transplantable, vascularized, and customizable bone, generated in a living organism for the reconstruction of load-bearing bone defects, individually tailored to the patient’s needs. With this approach in personalized medicine for the reconstruction of critical-size bone defects, regeneration of parts of the human body will become possible in the near future. npj Regenerative Medicine (2021) 6:49 ; https://doi.org/10.1038/s41536-021-00158-8 1234567890():,; INTRODUCTION vascular networks consisting of endothelial cells can be created Therapeutic options for bone defects that cannot heal sponta- directly within tissue replacement materials7. Vascularization may neously, the so-called critical-size bone defects, are still limited be further supported by the addition of endothelial cells and and often associated with a great social burden.
  • The Femoral Hernia: Some Necessary Additions

    The Femoral Hernia: Some Necessary Additions

    International Journal of Clinical Medicine, 2014, 5, 752-765 Published Online July 2014 in SciRes. http://www.scirp.org/journal/ijcm http://dx.doi.org/10.4236/ijcm.2014.513102 The Femoral Hernia: Some Necessary Additions Ljubomir S. Kovachev Department of General Surgery, Medical University, Pleven, Bulgaria Email: [email protected] Received 28 April 2014; revised 27 May 2014; accepted 26 June 2014 Copyright © 2014 by author and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Purpose: The anatomic region through which most inguinal hernias emerge is overcrowded by various anatomical structures with intricate relationships. This is reflected by the wide range of anatomic interpretations. Material and Methods: A prospective anatomic study of over 100 fresh cadavers and 47 patients operated on for femoral hernias. Results: It was found that the transver- salis fascia did not continue distally into the lymphatic lacuna. Medially this fascia did not reach the lacunar ligament, but was rather positioned above it forming laterally the vascular sheath. Here the fascia participates in the formation of a fossa, which varies in width and depth—the pre- peritoneal femoral fossa. The results did not confirm the presence of a femoral canal. The dis- tances were measured between the pubic tubercle and the medial margin of the femoral vein, and between the inguinal and the Cooper’s ligaments. The results clearly indicate that in women with femoral hernias these distances are much larger. Along the course of femoral hernia exploration we established the presence of three zones that are rigid and narrow.